Sir Marc Feldmann’s research over the last 30 years has focused on the understanding of autoimmune disease, specifically the treatment of rheumatoid arthritis (RA). Sir Marc, now at the Kennedy Institute of Rheumatology at Oxford University, championed the importance of antigen presentation and cytokines in autoimmunity, a concept that led to TNF-α blockade. This idea was considered heretical in the 1980s until he and Sir Ravinder Maini led clinical trials showing that blocking TNF-α effectively treated rheumatoid arthritis refractory to previous therapy. The TNF-α antibodies Remicade, Humira, and Enbrel are now the cornerstone of a $25 billion industry. For stories about getting Pharma to speed delivery to patients and the power of persistence, watch the full interview.